An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects with H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
Latest Information Update: 10 Jun 2025
At a glance
- Drugs AK 006 (Primary)
- Indications Chronic urticaria
- Focus Adverse reactions
- Sponsors Allakos
Most Recent Events
- 12 Mar 2025 According to an Allakos media release, company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives.
- 29 Jan 2025 Planned End Date changed from 1 Apr 2026 to 1 Jun 2025.
- 29 Jan 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Jun 2025.